Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 >= 1% status confers therapeutic sensitivity to Ipilimumab, Nivolumab in patients with Esophageal Squamous Cell Carcinoma.
Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.
This statement is based on a regulatory approval from the Health Canada:
YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.